Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinoma07/10/2023 - 06/30/2028 (PI)
NIH/National Cancer Institute5R01CA275015-02
The Boston University - UCLA Lung Cancer Biomarker Characterization Center09/01/2022 - 07/31/2027 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Cancer Institute5U2CCA271898-03
Data sample and extraction, sequencing, and QC on samples from the GWAS replication lung cancer study09/01/2024 - 08/31/2025 (PI)
NIH/National Cancer Institute
EXCAMP -- effect of military exposures on airway gene expression and molecular modifiers of lung cancer among military personnel07/01/2024 - 06/30/2025 (Subcontract PI)
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. USU Federal Med Sch
The American Lung Association (ALA) Lung Health Cohort06/15/2019 - 06/30/2025 (Subcontract PI)
Northwestern University NIH NHLBI5U01HL146408-06
The Boston University Clinical and Transitional Science Institute04/15/2020 - 03/31/2025 (Key Person)
PI:
Megan H. Bair-Merritt, MD, MSCENIH/National Center for Advancing Translational Sciences5UL1TR001430-09
Sequencing of nasal RNA from individuals at high risk for lung cancer01/01/2023 - 12/31/2024 (PI)
Inova Health Care Services
Transitions from Impaired Respiratory Health to Lung Disease01/01/2020 - 06/30/2024 (Subcontract PI)
Northwestern University NIH NHLBI5R01HL122477-07
Exploring the potential role of IL33 in bronchiectasis08/01/2023 - 02/29/2024 (PI)
Sanofi US Services Inc.
Impact of smoking and its cessation on systemic and airway immune activation07/01/2022 - 12/31/2023 (Subcontract PI)
Boston Medical Center Corporation NIH NIDA5R01DA042685-05
Showing 10 of 21 results.
Show All Results
Improving Outcomes After Lung Cancer Surgery01/01/2022 - 12/31/2023 (PI)
Ellison Foundation
mRNA expression sequencing analysis of nasal swabs from workers exposed to electronic waste processing in Accra, Ghana (CAS: 10821)09/21/2022 - 09/20/2023 (PI)
NIH/National Cancer Institute75N91022P00843
Molecular and Imaging biomarkers for early lung cancer detection in the setting of Indeterminate Pulmonary Nodules09/23/2016 - 08/31/2023 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Cancer Institute5R01CA210360-06
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers03/01/2019 - 03/01/2023 (Co-Investigator)
PI:
Ehab Billatos, MDJohnson & Johnson
The Boston University-UCLA Lung Cancer Biomarker Development Lab09/20/2016 - 09/30/2022 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Cancer Institute3U01CA214182-05S1
Integrated molecular, cellular and imaging characterization of screen-detected lung cancer09/16/2015 - 08/31/2021 (Multi-PI)
PI:
Marc Lenburg, PhDUniversity of California, Los Angeles NIH NCI3U01CA196408-05S1
Study BET inhibitors in COPD12/18/2017 - 02/28/2019 (PI)
AstraZeneca AB
Integrative Omics to Discover Molecular Determinants of COPD06/01/2016 - 05/31/2018 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Heart, Lung, and Blood Institute4R01HL118542-04
Molecular biomarkers of airway and lung linking COPD and Lung Cancer09/15/2011 - 07/31/2016 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Cancer Institute5R01CA164783-04
Integrative Omics to Discover Molecular Determinants of COPD08/15/2013 - 05/31/2016 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Heart, Lung, and Blood Institute5R01HL118542-03
Validation of a Genomic Biomarker of Responses to Environmental Tobacco Smoke08/08/2011 - 06/30/2015 (Multi-PI)
PI:
Marc Lenburg, PhDNIH/National Institute of Environmental Health Sciences5R01ES020425-02